Patents by Inventor Lucienne Chatenoud

Lucienne Chatenoud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10006903
    Abstract: The present invention relates to an in vitro use of a number of IL-4 and/or IL-13 secreting T-cells as a biomarker for diagnosing and/or monitoring an IgE-dependent allergic disease.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: June 26, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PIERRE ET MARIE CURIE—PARIS 6
    Inventors: Jocelyne Just, Benedicte Michaud, Jean-Francois Bach, Lucienne Chatenoud
  • Publication number: 20150024421
    Abstract: The present invention relates to an in vitro use of a number of IL-4 and/or IL-13 secreting T-cells as a biomarker for diagnosing and/or monitoring an IgE-dependent allergic disease.
    Type: Application
    Filed: July 22, 2014
    Publication date: January 22, 2015
    Inventors: Jocelyne JUST, Benedicte MICHAUD, Jean-Francois BACH, Lucienne CHATENOUD
  • Publication number: 20060188494
    Abstract: A method of treating spontaneous and ongoing auto-immune diseases in mammals, comprising administering to a mammal, in need of such a treatment, a therapeutically effective amount of one or more non mitogenic anti-CD3 active principles to achieve permanent disease remission through the induction of antigen-specific unresponsiveness, i.e. immune tolerance.
    Type: Application
    Filed: November 4, 2005
    Publication date: August 24, 2006
    Inventors: Jean-Francois Bach, Lucienne Chatenoud
  • Patent number: 7041289
    Abstract: A method of treating spontaneous and ongoing auto-immune diseases in mammals, comprising administering to a mammal, in need of such a treatment, a therapeutically effective amount of one or more non mitogenic anti-CD3 active principles to achieve permanent disease remission through the induction of antigen-specific unresponsiveness, i.e. immune tolerance.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: May 9, 2006
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean-Francois Bach, Lucienne Chatenoud
  • Publication number: 20040265276
    Abstract: A medical combination of at least one immunosuppressive agent and at least one recombinant adenovirus with a genome that includes a first recombinant DNA containing a therapeutic gene, and a second recombinant DNA containing an immunoprotective gene, for consecutive, intermittent and/or simultaneous use in in vivo and/or ex vivo exogenic transfections.
    Type: Application
    Filed: April 14, 2004
    Publication date: December 30, 2004
    Inventors: Michel Perricaudet, Lucienne Chatenoud, Hedi Haddada, Jean-Francois Bach, Michelle Webb
  • Publication number: 20030004091
    Abstract: A medical combination of at least one immunosuppressive agent and at least one recombinant adenovirus with a genome that includes a first recombinant DNA containing a therapeutic gene, and a second recombinant DNA containing an immunoprotective gene, for consecutive, intermittent and/or simultaneous use in in vivo and/or ex vivo exogenic transfections.
    Type: Application
    Filed: May 22, 1998
    Publication date: January 2, 2003
    Inventors: MICHEL PERRICAUDET, MARTIN LEE, LUCIENNE CHATENOUD, HEDI HADDADA, JEAN-FRANCOIS BACH, MICHELLE WEBB